1. **Introduction**
   1.1. Patent Ductus Arteriosus (PDA) is a common form of congenital heart disease. There is a persistent connection between the aorta and the pulmonary artery. As a result, there is continuous left to right shunting of blood. This in turn leads to volume and pressure overloading. Percutaneous closure of PDA is done by implanting a closure device across the defect. It is performed under the guidance of X-ray, through percutaneous method.

2. **Importance of Procedure**
   2.1. Patient with PDA may experience no symptoms in early years of life but may be complicated by pulmonary hypertension, congestive heart failure, arrhythmias and stroke starting from middle age. Timely closure of PDA may prevent such complications. Percutaneous closure is an alternative treatment method to the conventional surgical closure. In selected cases, percutaneous closure is successful in over 90% of cases. Patients who refuse this method can select either surgical closure or medical therapy.

3. **Before the Procedure**
   3.1. An echocardiogram (ultrasound imaging of your heart) will be performed to assess and confirm the location, size and functional significance of the PDA. Special attention will be taken on the feasibility of the percutaneous approach.
   3.2. You will be invited to a ward or a clinic for some preliminary tests including electrocardiogram, chest X-ray, and blood tests. We will also check your allergy history.
   3.3. Our medical staff will explain to you and your relatives the procedure and its risks, and present to you this information leaflet. You have to sign an informed consent.
   3.4. Blood thinning drugs may have to be stopped 3-5 days before the procedure. Steroid will be given if there is history of allergy. Antibiotic may be given as prophylaxis for the procedure.
   3.5. Fasting of 4-6 hours is required prior to the procedure. An intravenous drip will be set up. Shaving may be required over the puncture site.
   3.6. If you are a female, please provide your last menstrual period (LMP) and avoid pregnancy before the procedure as this procedure involves exposure to radiation.

4. **The Procedure**
   4.1. This is an invasive procedure that is performed under local anesthesia in a cardiac catheterization centre.
   4.2. Electrodes are adhered to the chest to monitor the heart rate and rhythm. Blood oxygen monitor through your finger tip will be set up. Measurement of blood pressure from your arm will be taken during the examination.
   4.3. A small wound is made at the groin for access to arteries or veins.
   4.4. Catheters are advanced to the heart. Pressures within the heart are measured. Aortic and pulmonary angiogram may be performed to delineate the anatomy of PDA. The degree of blood shunting is calculated.
   4.5. An appropriate closure device will be chosen according to the anatomy, size and length of PDA. The closure device will be deployed under x-ray guidance.
   4.6. Further angiogram will be performed to ensure successful closure.
5. After the procedure
5.1. After the procedure, catheters will be removed. The wound site will be compressed to stop bleeding.
5.2. Nursing staff will check your blood pressure, pulse and wound regularly.
5.3. Bed rest may be necessary for 4 hours. In particular, please do not move or bend the affected limb. Whenever you cough or sneeze, please apply pressure on the wound with your hand.
5.4. You should inform your nurse if you have any discomfort in particularly chest discomfort or find blood oozing from the wound site.
5.5. Once diet is resumed, please take more fluid to help eliminate contrast by passing urine.
5.6. Please follow instruction for the use of medications.

6. Follow Up
6.1. Usually you can be discharged 1-3 days after the procedure.
6.2. The wound will be inspected and covered with light dressing. Please keep the wound site clean and change dressing if wet. In general, showers are allowed after 2 days.
6.3. Please avoid vigorous activities (household or exercise) in the first 3 days after the procedure. Bruising around the wound site is common and usually subsides 2-3 weeks later. If you notice any signs of infection, increase in swelling or pain over the wound, please come back to the hospital or visit a nearby Accident and Emergency Department immediately.
6.4. Usually your doctor has explained to you the results of the procedure before discharge. Should you have further questions, you and your close relatives can discuss with your doctor during subsequent follow-up.

7. Risk and Complications
7.1. The procedure carries certain risks. Major complications (2-3%) include death, perforation of the heart chamber, stroke, infective endocarditis, device dislodgement, and partial obstruction of pulmonary artery. (Reference 1)
7.2. Minor complications (7%) include allergy to contrast reaction, nausea and groin complications. Bruising around the wound site is common.

8. Remarks
8.1. It is hard to mention all the possible consequences if this procedure is refused.
8.2. The list of complications is not exhaustive and other unforeseen complications may occasionally occur. The risk quoted is in general terms. In special patient group, the actual risk may be higher.
8.3. Should a complication occur, another life-saving procedure or treatment may be required immediately.
8.4. If there is further query concerning this procedure, please feel free to contact your nurse or your doctor.

9. Reference
I, ______________________ acknowledged that the above information concerning the operation or procedure has been explained by Dr ____________________. I have also been given the opportunity to ask questions and received adequate explanations concerning the condition and treatment plan.

<table>
<thead>
<tr>
<th>Name:</th>
<th>Patient Signature: __________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt No.:</td>
<td>Patient Name: ______________________________</td>
</tr>
<tr>
<td>Case No.:</td>
<td>Date: _____________________________</td>
</tr>
<tr>
<td>Sex/Age:</td>
<td>Unit Bed No.:</td>
</tr>
<tr>
<td>Case Reg. Date &amp; Time:</td>
<td></td>
</tr>
</tbody>
</table>

Version 1.0
Effective Date: 01/06/2017
Page 3 of 3